Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.22 USD | +1.76% | +8.21% | -3.51% |
10/05 | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
09/05 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.51% | 1.92B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-12.92% | 32.81B | |
+53.93% | 25B | |
-16.51% | 15.29B | |
-8.27% | 12.93B | |
-42.60% | 11.61B | |
-12.82% | 11.49B | |
+3.67% | 8.98B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals Insider Sold Shares Worth $1,396,780, According to a Recent SEC Filing